Serum albumin-binding domain antibodies (AlbudAbs) have previously been shown to greatly extend the serum half-life of the interleukin-1 receptor antagonist IL-1ra. We have subsequently extended this approach to look at the in vitro activity, in vivo efficacy and pharmacokinetics of an agonist molecule, interferon (IFN)-a2b, fused to an AlbudAb. Here we describe this molecule and show that in this format AlbudAb half-life extension technology displays significant advantages in comparison with other methods of half-life extension, in particular genetic fusion to serum albumin. When compared directly IFN-a2b fused to an Albudab shows higher potency, increased serum half-life and greater efficacy than human serum albumin fused to IFN-a2b. AlbudAbs are therefore an ideal platform technology for creation of therapeutics with agonist activity and long serum half-lives.
Introduction
Type I interferons (IFNs), including IFN-a2, are cytokines that have potent antiviral, anti-proliferative and immunomodulatory functions. Type I IFN production in response to viral infection is essential for antiviral defence as demonstrated by Ifnar1 knockout mice (Hwang et al., 1995) , which show high susceptibility to viral infection. IFN production in response to viral infection occurs through the recognition of pathogens via the toll-like receptors (Alexopoulou et al., 2001; Diebold et al., 2004) and results in the activation of several signal transduction pathways (Domanski et al., 1997; Li et al., 1997; reviewed in de Weerd, Samarajiwa and Hertzog, 2007) .
Constitutive low-level expression of IFN-a appears to be a prerequisite for enhanced production of IFN in response to stimuli (Brandt et al., 1994) , with IFN-induced proteins inhibiting viral replication via a number of mechanisms, including direct binding and degradation of viral RNA, prevention of the intracellular transport of viral particles, regulation of transcription and translation in the host cell, inhibition of viral replication and increased vulnerability of infected cells to virus-induced apoptosis (Marcus and Salb, 1966; Hovanessian, 1991; Hui et al., 2003; reviewed in Platanias, 2005) . Whilst promoting antiviral activity, type I IFNs also activate natural killer cells and dendritic cells, both important cell types in the onset of adaptive immunity (Luft et al., 1998; Swann et al., 2007) .
IFN-a in combination with the broad spectrum antiviral nucleoside Ribavirin has formed the cornerstone of therapy for chronic hepatitis C virus infections over the last 20 years. Patients treated with this combination drug regimen achieve sustained virologic response (SVR) in approximately 40% of cases (McHutchison et al., 1998; Poynard et al., 1998) following treatment for 24 -48 weeks with two to three subcutaneous administrations per week. Modification of recombinant IFN-a through addition of polyethylene glycol results in a biologically active molecule with improved pharmacokinetics (PK) (Glue et al., 2000) and allows more convenient once weekly dosing schedules. Patients receiving pegylated IFN-a/Ribavirin combination therapy achieve SVR in a greater number of cases compared with groups treated with IFN-a/Ribavirin (Manns et al., 2001) demonstrating the improved efficacy of extended-half-life IFN molecules. However both types of therapy are poorly tolerated with significant side-effects including flu-like symptoms, neuropsychiatric effects and haematological complications (Antonini et al., 2008; reviewed in Myint et al., 2009) .
IFN molecules with increased serum half-life in comparison with that of pegylated IFN may result in improved efficacy, lower incidence of adverse events and better patient compliance, mainly due to increased drug exposure and reduced dosing frequency. Osborn et al (2002) investigated the use of serum albumin fusion as an alternative half-life extension technology and produced a fusion protein termed 'Albuferon' which is comprised of human serum albumin (HSA) fused directly to the N-terminus of human IFN-a2b. Albumin is the most commonly occurring natural protein in blood with a half-life of around 19 days in man (Peters, 1977) and therapeutic proteins genetically fused to albumin have longer circulating half-lives and improved PK (Yeh et al., 1992; Syed et al., 1997) . In the study conducted by Osborn et al., Albuferon did indeed display the antiviral properties of IFN-a combined with an improved serum halflife in comparison with pegylated IFN. In a recent phase 2b trial directly comparing Albuferon and pegylated IFN similar efficacy and incidence of adverse events were observed between the two treatment groups (Zeuzem et al., 2008) . However in health surveys conducted as part of the study and designed to measure patient-reported quality of life ( physical functioning, bodily pain, general health, vitality, social functioning, emotional and mental health) the Albuferon treatment group scored better in comparison with the pegylated IFN treatment group. Such improvements in health-related quality-of-life scores coupled with a more convenient dosing schedule form the rationale behind the continued clinical development of Albuferon. The molecule is currently in phase III clinical trials and may replace pegylated IFN in the current standard of care for chronic HCV infection.
As a result of the success of the above studies, we have investigated an alternative half-life extension technology (AlbudAb TM ) utilising a serum albumin-binding domain antibody genetically fused to IFN-a2b. Domain antibodies (dAbs) are the smallest functional binding units of human immunoglobulins, comprising only a single heavy or light chain variable domain (Ward et al., 1989) . They are small (11 -13 kDa), highly stable and well-expressed proteins that have fully human scaffolds (Jespers et al., 2004) . Albumin-binding dAbs (AlbudAbs) with specificity for human, mouse and rat serum albumin have previously been identified and their half-lives shown to be similar to that of serum albumin (Holt et al., 2008) . AlbudAbs have also been shown to significantly increase the half-life of therapeutic molecules such as IL-1ra whilst maintaining in vivo efficacy (Holt et al., 2008) . Whereas IL-1ra exerts its therapeutic effect via antagonism of receptor -ligand interactions, the effect of AlbudAb fusion on the biodistribution, activity and PK and activity of an agonist such as IFN-a has not previously been investigated. We have therefore developed IFNa-AlbudAb fusions and compared the in vitro activity, serum half-life, antiviral potency and in vivo efficacy directly to that of HSA fused IFN-a2b.
Materials and methods

Cloning of IFN-a2b fusion proteins
IFN-a2b-DOM7 h-14 expression construct was cloned as follows: pDOM71, a derivative of pTT5 HEK293E expression vector (National Research Council, Canada) was prepared by insertion of a DOM7 h-14 encoding insert into pTT5. Briefly, DOM7 h-14 insert was amplified by PCR to append NheI and HindIII restriction sites using primers DX014 (5 0 -GCTAGCGATATCCAGATGACTCAATCTCCA AGTTC-3 0 ) and DX015 (5 0 -AAGCTTTTATTATCTCTTAA TCTCAACTTTAGT-3 0 ) and inserted into pCR-Zero Blunt topoisomerase cloning vector (Invitrogen). Error-free clones were obtained by sequencing with M13F and M13R primers and the DOM7 h-14 insert cloned into NheI/HindIII-digested pTT5. Human IFN-a2b insert was then amplified by PCR from a synthetic cDNA (DNA 2.0) to append a 5 0 BamHI restriction site, a 3 0 linker sequence and AvrII site before being inserted into pCR-Zero Blunt and sequenced using M13F and M13R primers. The BamHI/AvrII insert containing IFN-a2b-linker was then cloned into BamHI/NheIdigested pDOM71.
The HSA-IFN-a2b expression construct was cloned as follows: HSA-coding sequence was PCR amplified from P. pastoris strain GS115/His þ /Mut 2 /Sec HSA (Invitrogen) using primers DX129 (5 0 -AATTATGGATCCACCGGCGA TGCACACAAGAGTGAGGT-3 0 ) and DX130 (5 0 -CAGATC ACATAAGCCTAAGGCAGCTTGACT-3 0 ) to append 5 0 BamHI restriction site and 3 0 sequence encoding the N-terminal 3 residues of human IFN-a2b. In parallel human IFN-a2b-coding sequence was amplified using primers DX131 (5 0 -TTAGGCTTATGTGATCTGCCTCAAACCCAC-3 0 ) and DX050 (5 0 -AAGCTTTTATTATTCCTTACTTCTTA AACTTTCTTGCAAGTTT-3 0 ) to append 5 0 sequence encoding C-terminal 3 residues of HSA and 3 0 stop codons and HindIII restriction site. Assembly PCR to produce the fulllength HSA-IFN-a2b-coding sequence was then carried out using a mixture of HSA and IFN-a2b PCR fragments as template, priming with DX129 and DX050. Assembled HSA-IFN-a2b PCR product was then inserted into pCR Zero blunt and sequenced to obtain error-free clones before inserting into BamHI/HindIII-digested pTT5.
Expression and purification of IFN-a2b fusion proteins
For each expression construct plasmid DNA was prepared using a QIAfilter megaprep kit (Qiagen) using the endotoxinfree method as described by the manufacturer. One microgram DNA per ml of cell culture media was then transfected with 293-Fectin (Invitrogen) into HEK293E cells and grown in Gibco FreeStyle 293 expression medium (Invitrogen) supplemented with 1% (v/v) Pluronic (Invitrogen). Twenty-four hours after transfection, cells were supplemented with 0.5% (w/v) casein tryptone (Invitrogen). The protein was expressed in culture for 5 days (from the time of transfection) and purified from culture supernatant using protein L coupled to NHS streamline resin (GE Healthcare) in the case of IFN-a2b-DOM7 h-14 or Prometic Blue SA (Prometic Biosciences) in the case of HSA-IFN-a2b. Briefly proteins were bound to resin for 2 h at room temperature before washing with 10 column volumes of 1Â PBS and eluted from protein L in 0.1 M glycine pH 2.0 or from Prometic Blue SA in 1Â PBS supplemented with 0.5 M NaCl. Following elution from protein L, proteins were neutralised by addition of 1/10 volume 1 M Tris -HCl, pH 8. Purified proteins were then buffer exchanged into PBS in both cases.
HEK293 blue IFNa/b reporter cell assay for type I IFN activity IFN molecules were diluted to the required concentration in cell growth medium (DMEM supplemented with 4.5 g/l glucose, 10% heat-inactivated FBS, 30 mg/ml of blasticidin and 100 mg/ml of Zeocin) in the presence or absence of 100 mM HSA (Delta Biolabs) as required and transferred to 96-well assay plates in 20 ml per well volumes. HEK-Blue TM IFN-a/b cells (Invivogen) cultured between 70 and 80% confluency were prepared to a seeding concentration of 2.8 Â 10 5 cells per ml in cell growth medium and 180 ml of this cell suspension was transferred to each well of the assay plate. The assay plate was then incubated for 24 h at 378C, 5% CO 2 . The following day QUANTI-Blue TM reagent was prepared according to manufacturer's instructions and 160 ml per well added to 96-well microtiter plates. Forty microliters of supernatant from the induced HEK293-Blue IFN-a/b cells was then added to the QUANTI-Blue containing microtiter plate and the reaction incubated for 1 -3 h at 378C, 5% CO 2 before reading absorbance at 620 -655 nm in a Spectramax M5e plate reader (Molecular Devices).
Surface plasmon resonance assay
For analysis of IFN-a2b-DOM7 h-14 affinity for serum albumin, 500 resonance units of albumin were coupled to a CM5 Biacore chip at pH 5.5 using a BIAcore 3000 instrument (BIAcore) and binding curves generated by flowing IFN-a2b-DOM7 h-14 diluted in HBS-EP buffer (BIAcore) over a range of concentrations in the range of 5 nM to 5 mM across the Biacore chip. Affinity (K D ) was calculated by fitting on-rate and off-rate curves for traces generated in the range of the kDa for IFN-a2b-DOM7 h-14 using BIAeval software (BIAcore).
Drug administration and PK analyses
PK studies were conducted in male Sprague -Dawley rats and compounds were administered intravenously and subcutaneously (Taconic) at a target dose of 2 mg/kg in the case of IFN-a2b-DOM7 h-14 and HSA-IFN-a2b or 2.5 mg/kg in the case of IFN-a standard. Serum samples were collected after 0.17, 1, 2, 4, 7, 12, 24, 48, 72 and 96 h post-dose and analysed using the IFN-a Easy ELISA (GE Healthcare). The mean mg/ml value at each time point was then analysed in WinNonLin using non-compartmental analysis.
Encephalomyocarditis virus assay for antiviral activity IFN molecules were diluted to the required concentration in cell growth medium (DMEM supplemented with 10% newborn calf serum) in the presence or absence of 100 mM HSA as required and transferred to 96-well assay plates in 100 ml per well volumes. A549 cells were prepared to a seeding concentration of 8 Â 10 5 cells per ml in cell growth medium and 50 ml of this cell suspension was transferred to each well of the assay plate. The assay plate was incubated overnight at 378C, 5% CO 2 . The following day growth medium was removed from the assay plates and 100 ml per well EMC virus (BioReliance) diluted to a concentration of 1.32 Â 10 6 TCID 50 per ml in growth medium was added. Assay plates were incubated for 30 h at 378C, 5% CO 2 before determination of cell viability. Briefly growth medium containing EMC virus was removed from assay plate and replaced with 100 ml per well Alamar Blue stain (Invitrogen) diluted 25-fold in growth medium. Plates were then read using a Gemini plate reader (Molecular Devices) at excitation and emission wavelengths of 544 and 590 nm, respectively. Activity in international units per mg of protein (IU// mg) was calculated in comparison with the international reference standard material (National Institute for Biological Standards and Control).
518A2 tumor xenograft
The human melanoma cell line, 518A2 was obtained from Dr Clemens Krepler, University of Vienna. The cell line had been previously tested and found to be endotoxin and endogenous rodent pathogen free. The cells were maintained in Dulbecco's modified Eagle's culture medium supplemented with 10% fetal bovine serum (Invitrogen) and an antibiotic mixture containing 100 IU/ml of penicillin and 100 mg/ml of streptomycin (Invitrogen), in a fully humidified 5% CO 2 , 95% ambient air atmosphere at 378C. Cells were prepared for use by rinsing monolayers with Dulbecco's PBS lacking Ca 2þ and Mg 2þ prior to detachment by incubation in a solution of 0.05% trypsin -EDTA (Invitrogen). Cell numbers were assessed with a Guava Easycyte laser cytometer using Viacount software (Millipore) prior to resuspension at an appropriate density in PBS immediately prior to dosing.
Six to 8-week-old female SCID (CB17/ICR-Prkdcscid/ IcrCrl) mice were obtained from Charles River (UK) Ltd., and housed in pathogen-free conditions within positive pressure flexible film isolators. All work was performed and monitored with appropriate authority under the UK Animals (Scientific Procedures) Act 1986.
Following preparation, 0.1 ml (1 Â 10 7 ) cells were injected subcutaneously (s.c.) with a 25 mm, 25-gauge needle into the right subclavicular region of each mouse, allowing a somewhat remote injection point from the implant site in order to minimise cell leakage. Following consultation with statisticians, 10 mice were used per group.
Following inoculation, mice were checked daily for the occurrence of tumors at the implantation site. When animals had developed tumor nodules of $5 mm in diameter they were tail marked and study of drug administration was initiated. Two doses of drug were administered s.c. at 0.1 ml/kg 7 days apart and a control group was similarly dosed with PBS. The growth of tumors was monitored three times weekly by calliper measurement of tumor length (a) and width (b). Tumor volume was estimated by using the formula:
)p/6. Tumor volumes were not allowed to exceed 1500 mm 3 and mice were killed using a recognised humane method.
Results
Expression and in vitro activity of human IFN-a2b fusion proteins
Human IFN-a2b fusion proteins were cloned into pTT5-based expression vectors (Durocher et al., 2002) , transfected into HEK293E cells and purified directly from tissue culture supernatant following 5 day culture. Amino acid sequence of DOM7 h-14 AlbudAb selected by phage display (McCafferty et al., 1990; Winter et al., 1994) is shown in Fig. 1. IFN-a2b fused directly to the C-terminus of HSA (HSA-IFN-a2b) was purified on Prometic Blue SA affinity resin ( Fig. 2A, lane 2) . This molecule is essentially the same as Albuferon described previously (Osborn et al., 2002) and differs only in the expression system used. IFN-a2b fused to the N-terminus of DOM7 h-14 (IFN-a2b-DOM7 h-14) could be purified on protein L streamline (Fig. 2A, lane 3) . Bands of the correct size were obtained from both purifications; however, in the case of IFN-a2b-DOM7 h-14 a distinct doublet was observed. This most likely reflects the presence of post-translational modification of the mature polypeptide, as an O-linked glycosylation site is present at residue T106 of the mature polypeptide, with other modifications also reported (Adolf et al., 1991) . This doublet has also been observed previously when expressing IFN-a2b in the HEK293E system (Loignon et al., 2008) .
In order to determine whether purified fusion proteins were active, IFN activity was assayed using the HEK293 IFN-a/b cell line (Fig. 2B ) in which HEK293 cells are stably transfected with a secreted alkaline phosphatase (SEAP) reporter gene under the control of an IFN-inducible promoter element. Treatment of this cell line with type I IFN Fig. 1 . Amino acid sequence of DOM7 h-14 AlbudAb. DOM7 h-14 sequence was aligned with that of the amino acid sequence for the human DPK9 -Jk1 germline gene. DOM7 h-14 residues identical to the germline sequence are represented by '.'. Residue numbering was determined by the method of Kabat, with amino acid residues forming the three CDRs underlined. results in induction of reporter gene expression in a manner dependent upon the level of IFN activity. Both fusion proteins were capable of inducing reporter gene expression in this cell line, although with reduced in vitro potency in comparison with IFN-a standard (recombinant IFN-a2a expressed in Escherichia coli, R & D systems). In the absence of HSA, IFN-a2b-DOM7 h-14 was able to induce reporter gene expression with an apparent EC 50 of 4.8pM. This value is 8-fold higher than observed with IFN-a standard. HSA-IFN-a2b EC 50 in the same assay was 268pM, approximately 55-fold less potent than IFN-a2b-DOM7 h-14. In the presence of 100 mM HSA, the respective potencies of the IFN-a standard and HSA-IFN-a2b were largely unaffected, whereas the EC 50 of IFN-a2b-DOM7 h-14 was increased to 14pM, representing an approximately 3-fold reduction in potency, presumably due to steric effects following direct binding to HSA; however, IFN-a2b-DOM7 h-14 in vitro potency in the presence of serum albumin is approximately 18-fold higher than observed with HSA-IFN-a2b. Whilst the 100 mM concentration of HSA used in this assay is lower than the $600 mM concentration found in vivo, no differences were observed in this assay when the two concentrations of HSA were compared directly (not shown).
Serum albumin binding of human IFN-a2b fused to DOM7 h-14
The affinity of IFN-a2b-DOM7 h-14 for human, mouse and rat serum albumin was then determined by BIAcore analysis. The fusion protein was passed over the surface of a CM5 chip coated with SA and equilibrium dissociation constant, K D , determined as a measure of affinity using the 1:1 interaction model in BiaEval software (data not shown). Affinity of IFN-a2b-DOM7 h-14 for human, mouse and rat SA was approximately 254, 267 and 950 nM, respectively. Compared with the unfused DOM7 h-14 AlbudAb, this represents a decrease in affinity of 7.7, 22.3 and 15.8-fold for human, mouse and rat SA as a direct consequence of fusion to human IFN-a2b; however, these affinities are not dissimilar to those observed for other lower affinity albudAbs (Holt et al., 2008) .
PK analysis of human IFN-a2b fusion proteins
IFN-a2b fusion proteins were then subjected to a PK analysis in rats following intravenous dosing. The in vivo half-life of both fusion proteins were significantly increased in comparison with the IFN-a standard (Fig. 3A) . Similar AUC values were obtained for IFN-a2b-DOM7 h-14 and HSA-IFN-a2b, 737.5 and 689.2 h mg/ml, respectively, which in both cases represents a significant increase over the value of 18.8 h mg/ml observed with the IFN-a standard (Table I) . Similarly, the T 1/2 values for both fusion proteins were increased in comparison with that of IFN-a standard (22.6 and 14.2 h for IFN-a2b-DOM7 h-14 and HSA-IFN-a2b, respectively compared with 1.2 h for IFN-a standard). The T 1/2 of IFN-a2b-DOM7 h-14, however, is approximately 1.5 times longer than that of HSA-IFN-a2b.
A further study was carried out to determine PKs following subcutaneous administration in rat. As with the i.v. study the in vivo half-life of both fusion proteins was increased in comparison with IFN-a standard (Fig. 3B and Table II) ; however, both AUC and T 1/2 of IFN-a2b-DOM7 h-14 were increased when compared with values obtained with HSA-IFN-a2b (AUC 342.5 h mg/ml and T 1/2 of 28.3 h for IFN-a2b-DOM7 h-14 versus AUC 137.1 h mg/ml and T 1/2 of 19.7 h for HSA-IFN-a2b). Consistent with the improved in vivo half-life of IFN-a2b-DOM7 h-14 compared with HSA-IFN-a2b, the AlbudAb fusion protein was also cleared Table I . (B) Mean plasma concentration of IFN-a2b-DOM7 h-14 (closed squares) and HSA-IFN-a2b (closed traingles) following single-dose 2 mg/kg subcutaneous administration. Fusion proteins were injected separately into rats and serum analysed at the indicated time points with n ¼ 3 at each time point. For comparison IFN-a standard dosed at 2.5 mg/kg (closed circles) is also shown. PK parameters are shown in Table II . Long-acting interferon by fusion to anti-serum albumin dAb at a lower rate following subcutaneous administration (clearance rate of 5.9 ml/h/kg with IFN-a2b-DOM7 h-14 versus 16.7 ml/h/kg for HSA-IFN-a2b). Bioavailability following subcutaneous administration was also improved with IFN-a2b-DOM7 h-14 compared with HSA-IFN-a2b (46.4% versus 19.9%).
Antiviral efficacy of human IFN-a2b fusion proteins
In order to determine the in vitro antiviral efficacy of human IFN-a2b fusion proteins, we studied the effect of these molecules in a cell culture system in which the A549 human lung carcinoma cell line is infected with encephalomyocarditis virus (EMCV). In this assay the level of IFN-mediated protection against EMCV infection was determined for each fusion protein and the activity in international units per mg (IU/mg) calculated by comparison with the international reference standard material (National Institute for Biological Standards and Control). Since the in vitro potency of IFN-a2b-DOM7 h-14 appears to be slightly reduced in the presence of HSA (Fig. 2B) , we determined the in vitro antiviral efficacy of human IFN-a2b fusion proteins and the IFN-a standard in the absence or presence of 100 mM HSA. With 100 mM HSA the activity of both human IFN-a2b fusion proteins and the IFN-a standard were slightly reduced (Fig. 4) . IFN-a standard activity was 6.6 Â 10 7 IU/mg and in the same assay IFN-a2b-DOM7 h-14 and HSA-IFN-a2b activity were calculated at 3.8 Â 10 6 and 2.4 Â 10 5 IU/mg, respectively. In comparison with the IFN-a standard this represents a fold reduction in activity of 17.4 for IFN-a2b-DOM7 h-14 and 275 for HSA-IFN-a2b. When compared directly, the activity of IFN-a2b-DOM7 h-14, measured in IU/mg, is 15.8-fold greater than that of HSA-IFN-a2b. On a molar basis this is equivalent to a 5.8-fold increase in the in vitro antiviral efficacy of IFN-a2b-DOM7 h-14 in comparison with HSA-IFN-a2b; therefore, even in the presence of HSA the in vitro antiviral efficacy of IFN-a2b-DOM7 h-14 is significantly higher than that of HSA-IFN-a2b as would be expected based on the measure of in vitro potency obtained in the HEK293 Blue IFN-a/b reporter cell assay.
In vivo efficacy of human IFN-a2b fusion proteins in melanoma xenograft model
In order to study the in vivo efficacy of human IFN-a2b fusion proteins, we used a xenograft model in which human tumor cell lines were transplanted into SCID mice. Once tumors had been established following transplantation, the effect of treatment with human IFN-a2b fusion proteins on tumor growth was determined as a measure of in vivo efficacy. Female SCID (CB17/ICR-Prkdcscid/IcrCrl) mice were xenografted with the 518A2 human melanoma cell line and subcutaneous injections of vehicle control (PBS), or equimolar amounts of either IFN-a2b-DOM7 h-14 (8.75 mg/kg) or HSA-IFN-a2b (24 mg/kg) were administered on days 1 and 8 post-tumor implant (Fig. 5) . Both human IFN-a2b fusion proteins were able to significantly reduce the rate of increase in tumor volume as shown by comparison of measurements obtained from these two groups with those obtained from the vehicle control group; however, the reduction observed with the IFN-a2b-DOM7 h-14 group was greater than that observed in the HSA-IFN-a2b group. In order to determine whether these results were statistically significant, slopes of the graphs obtained (up to day 34) were compared using random coefficient regression analysis. The reduction in tumor growth rates in the IFN-a2b-DOM7 h-14 group was significantly different (P ¼ 0.001) compared with that of the HSA-IFN-a2b group.
The effect of a lower dose (0.875 mg/kg) of IFN-a2b-DOM7 h-14 in this model was also investigated and compared with mice receiving 24 mg/kg HSA-IFN-a2b, in this case with dosing on days 6 and 13 post-tumor implant. In both groups, a statistically significant reduction in Statistical comparison of the tumor volumes in the IFN-a2b-DOM7 h-14 and HSA-IFN-a2b dose groups was carried out using linear regression coefficient analysis and differences found to be significant (P ¼ 0.001). tumor growth was observed in comparison with the vehicle control group (data not shown); however, when compared directly the differences between the two groups was not statistically significant (P ¼ 0.0715). In addition, IFN-a2b-DOM7 h-14 was also observed to increase the time taken for 100% of mice to show measurable tumors in comparison with HSA-IFN-a2b (data not shown). These data demonstrate the improved in vivo efficacy of IFN-a2b-DOM7 h-14 compared with HSA-IFN-a2b in this model. When dosed at molar equivalence, a significantly greater reduction in tumor growth is observed in the IFN-a2b-DOM7 h-14 group. When IFN-a2b-DOM7 h-14 is administered at a 10-fold lower dose (on a mg/kg basis) than HSA-IFN-a2b the level of reduction in tumor growth is indistinguishable between the two groups.
Discussion
We have shown that AlbudAb half-life extension technology can be used to develop long-acting, highly potent and efficacious IFN molecules with superior properties to other extended half-life IFN molecules currently available or in development. In comparison with HSA-IFN-a2b, human IFN-a2b fused to an AlbudAb via a short peptide linker has improved in vitro potency in cell-based assays, longer serum half-life in PK studies following s.c. administration in rat, greater antiviral efficacy in tissue culture models of EMCV infection and significantly better in vivo efficacy in the melanoma xenograft model. This data demonstrates the potential utility of the AlbudAb format in the development of novel IFN therapies. IFN-a2b-DOM7 h-14 displays greater activity in cell reporter assays than HSA-IFN-a2b, even in the presence of high serum albumin concentrations. This could be due in part to steric effects, as in the case of HSA-IFN-a2b the SA molecule is fused directly to the N-terminus of IFN with no intervening linker sequence. In addition to steric hindrance due to direct HSA fusion there is also evidence to suggest that fusion to the N-terminal cysteine of IFN prevents correct formation of disulphide bonds (Zhao et al., 2007) , which may also affect IFN activity in this assay. Since IFN-a2b-DOM7 h-14 activity in this assay is greater than that of HSA-IFN-a2b even when the former is bound to HSA it does appear that both effects impact negatively on the activity of HSA-IFN-a2b.
Despite the apparent reduction in serum albumin-binding affinity of DOM7 h-14 after fusion to IFN, in rat PK studies, we still observed a significant improvement in the serum half-life of IFN-a2b-DOM7 h-14 in comparison with that of HSA-IFN-a2b. This may be due in part to the fact that DOM7 h-14 binds to domain 2 of HSA (data not shown) and therefore is unlikely to interfere with the interaction of HSA with FcRn, the MHC-related receptor, which protects HSA from degradation following binding to domain 3 of SA (Chaudhury et al., 2006) . HSA-IFN-a2b may be compromised in terms of FcRn binding due to steric hindrance as a result of IFN fusion to domain 3 of the albumin molecule.
In agreement with results obtained from cell-based assays used to measure in vitro potency of IFN, the antiviral efficacy of IFN-a2b-DOM7 h-14 was higher than that of HSA-IFN-a2b when the two fusion proteins were compared directly in the EMCV assay, which would suggest that in addition to the improved in vivo half-life of IFN-a2b-DOM7 h-14 this format of molecule could also prove to be a more efficacious therapeutic than HSA-IFN-a2b. This is further supported by our observation that IFN-a2b-DOM7 h-14 has considerably improved efficacy in vivo, as shown by the dramatic reduction in tumor volume mediated by this molecule in the human melanoma 518A2 xenograft model. In these experiments, we observed a comparable reduction in tumor volume with IFN-a2b-DOM7 h-14 and HSA-IFN-a2b, even when the dose of the former was reduced by 10-fold in comparison with the latter. When the two molecules were dosed at molar equivalence, we observed a statistically significant increase in the efficacy of the IFN-AlbudAb fusion protein in comparison with the HSA-IFN fusion. This effect is likely to be a direct result of the increased in vivo half-life combined with the improved potency of IFN when fused to an AlbudAb.
In summary, we have used AlbudAb half-life extension technology to improve the PKs of therapeutics with agonist activity, such as IFN-a, and developed novel IFN-a molecules with significantly improved in vitro potency, in vivo half-life and in vivo efficacy compared with that observed with other half-life extension technologies, in particular genetic fusion to serum albumin.
